本文選題：乳腺癌 + 術(shù)后發(fā)熱��； 參考：《實(shí)用癌癥雜志》2016年12期

【摘要】：目的探討檢測(cè)血清降鈣素原在乳腺癌術(shù)后發(fā)熱患者中的變化,并分析其臨床應(yīng)用價(jià)值。方法采取回顧性方法對(duì)80例乳腺癌發(fā)熱的患者臨床資料進(jìn)行分析,且依據(jù)患者的臨床癥狀與病原學(xué)的檢查情況將其分為病原學(xué)陽(yáng)性組與發(fā)熱原因不明組以及臨床診斷感染組,檢測(cè)3組血清中降鈣素原的表達(dá)水平,分析其臨床應(yīng)用價(jià)值。結(jié)果病原學(xué)陽(yáng)性組降鈣素原含量為(7.8±2.1)ng/m L,臨床診斷感染組降鈣素原含量為(2.6±0.6)ng/m L,發(fā)熱原因不明組降鈣素原含量為(0.5±0.1)ng/m L,3組間數(shù)據(jù)比較,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。不同年齡、是否絕經(jīng)、是否淋巴結(jié)轉(zhuǎn)移和發(fā)熱程度以及不同化療方案各組中≤0.5 ng/m L、0.5~2.0 ng/m L、2.1~10.0 ng/m L、10.0 ng/m L的比例比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。病原學(xué)陽(yáng)性組降鈣素原含量陽(yáng)性表達(dá)率高于臨床診斷感染組、發(fā)熱原因不明組,3組降鈣素原陽(yáng)性表達(dá)率比較,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論臨床中檢測(cè)血清中降鈣素原對(duì)乳腺癌術(shù)后發(fā)熱性質(zhì)能進(jìn)行較好地鑒別與診斷,且該指標(biāo)檢測(cè)并不受患者的年齡和絕經(jīng)狀況以及淋巴結(jié)是否轉(zhuǎn)移與發(fā)熱程度以及不同化療方案等因素影響,臨床應(yīng)用價(jià)值高。
[Abstract]:Objective to investigate the changes of serum procalcitonin in patients with postoperative fever of breast cancer and to analyze its clinical value. Methods the clinical data of 80 patients with breast cancer fever were analyzed retrospectively. According to the clinical symptoms and etiology of the patients, the patients were divided into three groups: etiology positive group, fever unknown group and clinical infection group. The expression of procalcitonin in serum of three groups was detected and its clinical application value was analyzed. Results the content of procalcitonin was (7.8 鹵2.1) ng/m / L in the positive group, (2.6 鹵0.6) ng/m / L in the clinically diagnosed infection group and (0.5 鹵0.1) ng/m / L in the group with unknown fever cause. The difference was statistically significant (P0.05). There was no significant difference between different age, menopause, lymph node metastasis and fever, and the proportion of 鈮，

本文編號(hào)：2090392